The NDA has been accepted for UGN-102 for intravesical solution for low-grade intermediate-risk non-muscle invasive bladder cancer.

The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...

A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...

UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

UroGen Pharma new drug application for UGN-102, an investigational drug to treat certain types of bladder cancer, was approved by Food and Drug Administration. The company said on Tuesday that UGN-102 ...

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on URGN stock, giving a Buy rating today. Ram Selvaraju has given ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has ...

UGN-103 is anticipated to be a follow-up treatment to UGN-102, also based on mitomycin for the intravesical solution, which is awaiting potential FDA approval and commercial launch for the same ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Urogen Pharma (URGN – Research Report), with a ...